Navigation Links
Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
Date:10/30/2008

tology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need.

Halozyme Contact

Robert H. Uhl

Senior Director, Investor Relations

(858) 704-8264

ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics to Present at Upcoming Investor Conferences
2. Halozyme Therapeutics to Host Research Day for Investors and Analysts
3. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
4. Halozyme Therapeutics to Present at Upcoming Investor Conferences
5. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) has ... of bio-succinic acid used to produce a new ... that Bayer MaterialScience has begun commercializing.    ... eco, a series of bio-based waterborne polyurethane dispersions ... 65%.  IMPRANIL ® eco has been developed ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
(Date:4/23/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter 2015 results before the Nasdaq market opens on ... conference call and webcast to discuss its financial results ... 2015 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... call by dialing 866-952-1906 (US) or 785-424-1825 (International) using ...
Breaking Biology Technology:Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2
... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... enhanced the abilities of the molecules they are creating ... molecular complexes enter cancer cells and, when signaled, deliver ... new supermolecules have more units that will absorb light ... frequencies that can be included and excluded as signals ...
... DNA isn't just for storing genetic codes any more. ... into larger structures -- scientists have been using it ... even working mechanical devices. , Now Cornell University researchers ... could be used for drug delivery and as containers ...
... have become invaluable decision-making tools for public health ... epidemic of 2001, models can be useful in ... of an infection and they can allow the ... models make implicit assumptions that may systematically bias ...
Cached Biology News:Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 3Self-assembled DNA buckyballs for drug delivery 2Self-assembled DNA buckyballs for drug delivery 3Understanding biases in epidemic models important when making public health predictions 2
... plus,for Reliable Sterile Filtration of Tissue Culture ... pump or tube pump, quickly and,reliably sterilize ... aqueous solutions. The combination of a ... de-aeration,ensures high flow rates and optimal total,throughputs. ...
... Luminometer has been designed,for the detection ... measurements of glow and flash luminescence ... light remain nearly constant,over a longer ... for very fast reactions,requiring at least ...
... is a new generation of microarrays to ... enables you to rapidly elucidate alternatively spliced ... relevant for drug discovery. The service combines ... design and customized analysis with Agilents robust ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
Biology Products: